Promising 85% Response: Ru-D Regimen Shows Hope for Adults with HLH
Blood Journals Portfolio recently shared a post on X:
”The Ru-D regimen was well tolerated, resulting in OS rates of 85.7%, 67.9%, and 53.6% at 2 months, 6 months, and 2 years, respectively.”
Read the full article here.
The recently published article ”Ruxolitinib combined with dexamethasone for adult patients with newly diagnosed hemophagocytic lymphohistiocytosis in China” by De Zhou et al. in Blood sheds light on the possible positive results from combination of Ruxolitinib with Dexamethasone in HLH patients.
A phase 2 trial of the Ru-D regimen—ruxolitinib combined with dexamethasone—showed promising results in adults newly diagnosed with HLH of unknown triggers.
Among 28 patients, the overall response rate was 85.7%, with a 2-month overall survival rate of 85.7% and favorable 2-year survival in non-lymphoma-associated HLH cases.
The Ru-D regimen was well tolerated, supporting further investigation in a phase 3 trial.
Latest scientific advancements in hematology featured in Hemostasis Today.
-
Sep 6, 2025, 14:04Chokri Ben Lamine – VTE Prophylaxis in Pregnancy (ASH 2018 Guidelines)
-
Sep 6, 2025, 13:48The Body Explained on Blood Clotting Pathways
-
Sep 5, 2025, 14:06Thrombosis Update: VTE Death Rate 3X Higher in Los Angeles Jails Than General Population
-
Sep 5, 2025, 10:59New Study Featured by Rare Disease Advisor Reveals Quality-of-Life Challenges in Hemophilia
-
Sep 4, 2025, 22:00Shivani Modi Highlights SOHO 2025 Study Linking Elevated WBC Counts to Increased Thrombosis Risk
-
Sep 6, 2025, 16:43Khaled Musallam: de-LIGHT Study on Use of Lifetime Anemia and Iron Control Index (LAICI) in Thalassemia Treatment
-
Sep 6, 2025, 15:06Managing Gynecologic Bleeding in Anticoagulated Patients: Toolkit Co-Authored by Divyaswathi Citla Sridhar
-
Sep 6, 2025, 14:30Mattia Galli on Whether Reduction in MACE Really Depicts Situation in Spontaneous MI or Death post-PCI
-
Sep 6, 2025, 13:55Patrick Cieran Gallogly and Colleagues on Atypical Symptoms in TIA and Minor Stroke
-
Sep 6, 2025, 13:37Unfractionated Heparin Dosing in ECMO: A Systematic Review and Meta-Analysis
-
Sep 2, 2025, 13:53Cost-Effective Strategies to Reduce Anaemia Highlighted in The Lancet Haematology
-
Sep 2, 2025, 13:04Ischemic Stroke or TIA Linked to Higher Femoral Fracture Risk
-
Sep 2, 2025, 12:51Treatment of Deep Brain AVMs Tied to Increased Hemorrhagic Stroke Risk
-
Aug 29, 2025, 09:03Vasculearn Network: New 2025 High Blood Pressure Guidelines Are Here
-
Aug 18, 2025, 23:56Dr. Arun V. J Invites You to His Lecture on ‘AI and Data Sciences in Transfusion Medicine’ at the AI in Healthcare Conclave. Register now!
-
Sep 6, 2025, 14:09Erin VanDyke: Shifting Attention Upstream in VTE Care Through NBCA Centers of Excellence
-
Sep 6, 2025, 12:02Caitlin Raymond on Kairos in Medicine: How Curiosity Sustains Physicians and Prevents Burnout
-
Sep 5, 2025, 14:12EAHAD Podcast: Reducing Pain and Distress in Children Receiving Emicizumab
-
Sep 5, 2025, 10:58Côme Bommier Recommends CRTH for Clinical Trial Training and Career Growth in Hematology
-
Sep 5, 2025, 10:55EHC This Way Webinar: Enhancing Joint Health Through Exercise - 8 Sept